IMPORTANCE The aggressive triple-negative phenotype of breast cancer (negative for estrogen and progesterone receptors and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2] [formerly human epidermal growth factor receptor 2 (HER2)]) is considered by some investigators to be a relative contraindication to breast-conserving therapy. OBJECTIVES To compare outcomes of breast...

BACKGROUND Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast cancer, characterized by higher incidence in young women and a very poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs playing significant role in the pathogenesis of...

Breast cancer is the second leading cause of cancer death in women. Approximately 15-20% are triple negative breast cancer (TNBC: no protein expression of estrogen receptor, progesterone receptor, nor human epidermal growth factor receptor 2), representing one of the most challenging molecular subtypes of breast cancer. TNBC encompasses a heterogenous group of breast cancers that are not genera...

Abstract Purpose of Review Triple-negative breast cancer (TNBC) represents about 15–20% all cancers and often presents as an aggressive with poor prognosis compared to other forms cancer. This article will review the clinical manifestations, imaging features, pathology correlation, treatment management, TNBC. Recent Findings While mammography ultrasound can be used diagnose TNBC, MRI is most ac...

Several data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion. Vascular endothelial growth factor is the most important angiogenic factor with proven significance in breast cancer, as it has been ...

OBJECTIVE Our aim was to determine whether triple-negative breast cancer (TNBC) has distinguishing sonographic features compared to non-TNBC. METHODS Data from 145 consecutive breast cancer patients were collected. The images were reevaluated by two dedicated breast imaging experts according to the Breast Imaging Reporting and Data System. The sonographic features of 45 TNBC patients were com...

background: for xenograft models of triple-negative breast cancer (tnbc) to be valuable in development of molecularly-targeted drugs, careful characterization is essential to their validation. the present study aimed to validate the tnbc xenograft model with a specific focus on angiogenesis. methods : twelve tnbc xenograft tumors and 12 human breast cancer tumors (htnbc) were included in this s...

PURPOSE Triple negative breast cancer (TNBC) constitutes 10-15% of female breast cancers, and clinical guidelines recommend treatment with chemotherapy and surgery. We examined the recorded treatment and survival of women with TNBC in a population-based sample within the UK. METHODS Cancer registration data for North East London women diagnosed between 2005 and 2007 were supplemented with pat...

Breast cancer is a heterogeneous disease that can be characterized by different patterns of histology, receptor status as well as gene and molecular classifications. All these factors influence the therapy, the prognosis and the outcome for each individual patient. Triple-negative breast cancer (TNBC) is a certain subgroup of breast cancer that is negative for hormone receptors (ER and PR) and ...